Biologic Therapies (e.g., Dupilumab) for Chronic Rhinosinusitis with Nasal Polyps

Type: drug

Status: FDA Approved

Developer: Sanofi and Regeneron Pharmaceuticals

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026